The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Assessing capmatinib for lung cancer
Shobhit Baijal, MBBS, MRCP, MRCP, The University Hospital Birmingham NHS Trust, Birmingham, UK, discusses recent advances in the lung cancer treatment landscape including capmatinib, which targets MET exon 14 skipping (METex14) mutations in lung cancer. The accelerated approval process devised by regulatory authorities has enabled more drugs to be used in the clinic and Dr Baijal additionally highlights novel checkpoint inhibitors that may be approved in the UK. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
Disclosures
Dr Baijal has received honoraria from: Abbvie, Amgen, AstraZeneca, Boehringer Ingleheim, Bristol Myers-Squibb, Chugai, Daiichi Sankyo, FoundationOne, GlaxoSmithKline, Janssen, Lilly, Merck Serono, Novartis, Pierre Fabre, Pfizer, Roche, Servier, Sanofi and Takeda.
